Research programme: anti-adrenomedullin monoclonal antibodies - Adrenomed

Drug Profile

Research programme: anti-adrenomedullin monoclonal antibodies - Adrenomed

Latest Information Update: 19 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adrenomed
  • Class Monoclonal antibodies
  • Mechanism of Action Adrenomedullin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Septic shock

Most Recent Events

  • 19 Dec 2016 Development of monoclonal antibody therapies still ongoing for Sepsis and Septic shock (Adrenomed website, December 2016)
  • 19 Dec 2016 Adrenomed has issued and pending patents for anti-adrenomedullin antibodies in Europe and USA (Adrenomed website, December 2016)
  • 02 Jan 2013 Preclinical trials in Septic shock in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top